All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?
ZUMA 2: How does prior BTK inhibitor treatment affect the efficacy of KTE-X19 in patients with MCL?
Wang reports on data from the ZUMA 2 trial. He comments on the effect that prior exposure to Bruton's tyrosine kinase (BTK) inhibitors can have in patients with relapsed/refractory mantle cell lymphoma (MCL) being treated with KTE-X19.
Updated results from ZUMA-2 trial investigating KTE-X19 in R/R mantle cell lymphoma
During the 47th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), investigators presented results from the latest analyses of the...
Which patients with R/R MCL benefit from CAR-T therapy?
Michael Wang talks about mantle cell lymphoma (MCL) and the results of the ZUMA-2 clinical trial. Treatment for MCL has evolved from chemotherapy, through targeted therapy, to cell and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox